Literature DB >> 27371634

Molecular Profile and FDG-PET Metabolic Volume at Staging in DLBCL-Response.

Anne-Ségolène Cottereau1, Hélène Lanic2, Sylvain Mareschal3, Michel Meignan4, Pierre Vera5, Hervé Tilly2, Fabrice Jardin2, Stéphanie Becker5.   

Abstract

Mesh：

Substances：

Year:  2016        PMID： 27371634     DOI： 10.1158/1078-0432.CCR-16-0783

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


× No keyword cloud information.
  6 in total

1.  Predictive value of 18F-FDG PET/CT in adults with T-cell lymphoblastic lymphoma: post hoc analysis of results from the GRAALL-LYSA LLO3 trial.

Authors:  Stéphanie Becker; Thomas Vermeulin; Anne-Ségolène Cottereau; Nicolas Boissel; Pierre Vera; Stéphane Lepretre
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-07-21       Impact factor: 9.236

2.  Prognostic value of metabolic tumour volume on baseline 18F-FDG PET/CT in addition to NCCN-IPI in patients with diffuse large B-cell lymphoma: further stratification of the group with a high-risk NCCN-IPI.

Authors:  Qaid Ahmed Shagera; Gi Jeong Cheon; Youngil Koh; Min Young Yoo; Keon Wook Kang; Dong Soo Lee; E Edmund Kim; Sung-Soo Yoon; June-Key Chung
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-04-02       Impact factor: 9.236

3.  PET-derived tumor metrics predict DLBCL response and progression-free survival.

Authors:  Prioty Islam; Jordan Goldstein; Christopher R Flowers
Journal:  Leuk Lymphoma       Date:  2019-02-04

4.  Metabolic Tumor Volume in Lymphoma: Hype or Hope?

Authors:  Heiko Schöder; Craig Moskowitz
Journal:  J Clin Oncol       Date:  2016-10-20       Impact factor: 44.544

5.  Serum level of soluble interleukin-2 receptor is positively correlated with metabolic tumor volume on 18 F-FDG PET/CT in newly diagnosed patients with diffuse large B-cell lymphoma.

Authors:  Hajime Senjo; Minoru Kanaya; Koh Izumiyama; Koichiro Minauchi; Kenji Hirata; Akio Mori; Makoto Saito; Masanori Tanaka; Hiroaki Iijima; Eriko Tsukamoto; Kazuo Itoh; Shuichi Ota; Masanobu Morioka; Daigo Hashimoto; Takanori Teshima
Journal:  Cancer Med       Date:  2019-02-20       Impact factor: 4.452

6.  Integration of Baseline Metabolic Parameters and Mutational Profiles Predicts Long-Term Response to First-Line Therapy in DLBCL Patients: A Post Hoc Analysis of the SAKK38/07 Study.

Authors:  Sofia Genta; Guido Ghilardi; Luciano Cascione; Darius Juskevicius; Alexandar Tzankov; Sämi Schär; Lisa Milan; Maria Cristina Pirosa; Fabiana Esposito; Teresa Ruberto; Luca Giovanella; Stefanie Hayoz; Christoph Mamot; Stefan Dirnhofer; Emanuele Zucca; Luca Ceriani
Journal:  Cancers (Basel)       Date:  2022-02-17       Impact factor: 6.639
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.